Moreover, key regulators and emerging drug targets such as CEPT and APO(a) could be detected and quantified in chimeric mice, and the dyslipidemia was corrected with AAV9–LDLR gene therapy. The gene discussed is LDLR; the disease is metabolic syndrome.